On the evening of January 20, Shandong Wohua Pharmaceutical Co.Ltd(002107) (002107) released the annual report of 2021, which realized a revenue of 943 million yuan in 2021, a year-on-year decrease of 6.3%; The net profit was 163 million yuan, a year-on-year decrease of 8.66%; The basic earnings per share is RMB 0.28, and the net operating cash flow is about RMB 200 million.
At the same time, Shandong Wohua Pharmaceutical Co.Ltd(002107) announced that it plans to distribute a cash dividend of RMB 2.60 per 10 shares to all shareholders, with a total cash dividend of RMB 150 million, accounting for 91.85% of the net profit attributable to the parent company in the same period.
Shandong Wohua Pharmaceutical Co.Ltd(002107) pointed out that the prices of raw materials, packaging materials and energy of traditional Chinese medicine rose sharply in 2021, and the occasional regional epidemic hindered the company’s marketing. Facing the severe situation, Shandong Wohua Pharmaceutical Co.Ltd(002107) on the one hand, optimize the production process, improve procurement accuracy and reduce costs. On the other hand, pay equal attention to independent R & D and joint R & D, tap the clinical value of products, continue to deepen marketing reform, promote academic marketing, optimize organizational structure and market layout, promote intelligent manufacturing and strengthen information construction.
According to the data, Shandong Wohua Pharmaceutical Co.Ltd(002107) focuses on the field of cardiovascular and cerebrovascular Chinese patent medicine. It is a Chinese patent medicine enterprise integrating R & D, production and sales. It has a strong exclusive product line supported by four exclusive medical insurance products: wohua Xinkeshu tablets, Gushukang capsules / granules, Hedan tablets / capsules and Naoxueshu oral liquid.
It is understood that by the end of 2021, the volume of Chinese patent medicine will be purchased intensively, and the “boots” will be put on the ground. On December 21, 2021, the inter provincial Alliance for Chinese patent medicine of 19 provinces (cities and districts) led by Hubei Province officially released the results of the proposed selection. The average price drop reached 42.3%. The ginkgo leaf group in the cardiovascular field hit the highest drop of 82.6% and the lowest price of 8 cents per chip. The prices of Xueshuantong and Xuesaitong injections were halved. Guangdong and Shandong also began to organize the inter provincial Alliance for traditional Chinese medicine.
Shandong Wohua Pharmaceutical Co.Ltd(002107) said that although the company’s varieties have not entered yet, the impact of centralized procurement on the regional market pattern should not be underestimated. The competitive environment is changing. At the same time, the company’s products may enter the scope of centralized procurement at any time, and there is uncertainty in future sales performance. Once the company’s products enter the centralized purchase list, the price will drop significantly, which will affect the sales revenue and profit.
At the same time Shandong Wohua Pharmaceutical Co.Ltd(002107) also said that in order to prevent the risk of price reduction, the company has continuously strengthened the construction of academic brand, expanded market coverage and optimized market structure for many years, so that more doctors and patients recognize the product value.
It is understood that at the end of last year, Xinkeshu tablets, one of the pillar products of Shandong Wohua Pharmaceutical Co.Ltd(002107) , changed from medical insurance “class B” to “class a”, and the drug expenses changed from partial reimbursement to full reimbursement. According to the data of Intranet, in the first half of 2021, Xinkeshu tablet ranked second among public, urban community, county-level public and township health oral tablets for cardiovascular diseases.
In addition, Shandong Wohua Pharmaceutical Co.Ltd(002107) also pointed out that in 2021, the company continued to increase R & D investment and insisted on paying equal attention to independent R & D and joint R & D. According to the data, in 2021, Shandong Wohua Pharmaceutical Co.Ltd(002107) R & D investment was 47.478 million yuan, accounting for 5.04% of the operating revenue. The company said that in the future, it will accelerate the research and development of exclusive traditional Chinese medicine or increase product indications, enter more diagnosis and treatment schemes of integrated traditional Chinese and Western medicine, participate in the formulation of diagnosis and treatment schemes with traditional Chinese medicine characteristics, and continuously improve the clinical value of products.
It is worth noting that at present, a new round of annual report disclosure season is quietly approaching. Previously, on the evening of January 18, Huasu Holdings Co.Ltd(000509) released the first annual report of Shanghai and Shenzhen in 2021. In addition to Shandong Wohua Pharmaceutical Co.Ltd(002107) , two listed companies will disclose annual reports before the Spring Festival, namely Shanghai Kaikai Industry Company Limited(600272) (January 28) and Bus Online Co.Ltd(002188) (January 29).
In addition, at present, more than 200 listed enterprises have disclosed performance forecast related data, and most of them show performance forecast. Among them, the performance of chemical, pharmaceutical, electronic and other industries is bright, and those that have disclosed performance forecast in iron and steel, nonferrous metals and other industries also maintain a good growth level.
